MSCs for diabetes

Luca A Inverardi, Giacomo Lanzoni, Juan Dominguez-Bendala, Camillo Ricordi

Research output: Chapter in Book/Report/Conference proceedingChapter

2 Scopus citations

Abstract

Mesenchymal stromal cells (also often referred to as mesenchymal stem cells, MSCs) hold promise as a powerful tool in the treatment of human diseases. Because of their potent immunomodulatory properties, they are likely to impact in a positive fashion diseases in which inflammation and/or autoimmunity play a key role. Furthermore, they have been shown to possess plasticity as precursors of cells of various types. Their differentiation potential could span cell differentiation products that do not normally derive from the mesoderm, including cells of endodermal origin. These two remarkable features make them potentially ideal candidates for regenerative approaches. This chapter will briefly discuss the current state of the art in the emerging field of their use for autoimmune type 1 diabetes.

Original languageEnglish (US)
Title of host publicationMesenchymal Stromal Cells
Subtitle of host publicationBiology and Clinical Applications
PublisherSpringer New York
Pages571-597
Number of pages27
ISBN (Electronic)9781461457114
ISBN (Print)9781461457107
DOIs
StatePublished - Jan 1 2013

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Fingerprint Dive into the research topics of 'MSCs for diabetes'. Together they form a unique fingerprint.

  • Cite this

    Inverardi, L. A., Lanzoni, G., Dominguez-Bendala, J., & Ricordi, C. (2013). MSCs for diabetes. In Mesenchymal Stromal Cells: Biology and Clinical Applications (pp. 571-597). Springer New York. https://doi.org/10.1007/978-1-4614-5711-4_33